NasdaqGM:ORKABiotechs
Assessing Oruka Therapeutics (ORKA) Valuation After Encouraging ORKA 002 Phase 1 Trial Results
Oruka Therapeutics (ORKA) drew fresh investor attention after reporting encouraging interim Phase 1 data for ORKA-002, highlighting a long half-life and sustained IL-17 inhibition that could support less frequent dosing in psoriasis and hidradenitis suppurativa.
See our latest analysis for Oruka Therapeutics.
The positive ORKA-002 readout and recent conference presence appear to have kept interest high, with a 1-day share price return of 2.77% and year to date share price return of 18.15%...